Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 12.8% – What’s Next?

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) was down 12.8% during trading on Wednesday . The stock traded as low as $261.27 and last traded at $261.27. Approximately 105 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 317 shares. The stock had previously closed at $299.45.

Bio-Rad Laboratories Trading Up 1.1%

The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.37 and a current ratio of 3.21. The firm has a market cap of $7.05 billion, a PE ratio of 43.04 and a beta of 0.96. The stock has a 50-day simple moving average of $276.49 and a two-hundred day simple moving average of $295.24.

Bio-Rad Laboratories (NYSE:BIO.B) last announced its quarterly earnings results on Thursday, April 30th. The company reported $1.89 earnings per share (EPS) for the quarter. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.